<DOC>
	<DOCNO>NCT01558219</DOCNO>
	<brief_summary>This study design evaluate safety biweekly cabazitaxel treatment metastatic castration resistant prostate cancer ( mCRPC ) patient previously treat docetaxel contain regimen . The primary endpoint safety . Secondary endpoint include time treatment failure , response rate , overall survival quality life .</brief_summary>
	<brief_title>Second-line Chemotherapy Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>The objective study explore new , biweekly schedule cabazitaxel metastatic castration resistant prostate cancer patient . A previous study show biweekly administration docetaxel 1st line set mCRPC well tolerate docetaxel administer every three week . Also , efficacy biweekly docetaxel good three-weekly docetaxel biweekly dose present significant overall survival benefit ( ASCO 2011 , Kellokumpu-Lehtinen et al . As occurrence neutropenia TROPIC trial rather high , hypothesis reduce incidence severe adverse event administrate cabazitaxel frequently , yet maintain dose intensity every three weeksÂ´ dose schedule . This study design evaluate safety biweekly cabazitaxel treatment 60 patient metastatic castration resistant prostate cancer ( mCRPC ) patient previously treat docetaxel contain regimen .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Metastatic castration resistant prostate cancer Disease progression docetaxelcontaining regimen mCRPC Surgical medical castration WHO performance status &lt; 2 Age &gt; 18 year Adequate bone marrow , liver renal function : Hematology : neutrophil &gt; 1.5 x 109/ l hemoglobin &gt; 100 g/l platelet &gt; 100 x 109/l Hepatic renal function : total bilirubin &lt; 1 x ULN ALAT ASAT &lt; 2.5 x ULN , alkaline phosphate &lt; 6 x ULN.In presence extensive bone disease , alkaline phosphate &gt; 6 x ULN accept creatinine &lt; 1.5 x ULN ( ie NCI CTCAE grade &lt; 1 ) Prior surgery , radiation , chemotherapy , anticancer therapy within 4 week prior enrollment Prior therapy radioisotopes Other malignant disease ( except superficial nonmelanoma skin cancer ) within past 5 year Serious liver disease History severe hypersensitivity reaction ( grade &gt; 3 ) polysorbate 80 contain drug Concurrent plan treatment potent inhibitor inducers cytochrome P450 3A4/5 ( one week washout period necessary patient already treatment ) Other serious illness medical condition : Serious cardiac disease ; ischemic thromboembolic cardiac disease , pulmonary embolus , cardiac infarction within 12 month Active infection Active peptic ulcer , uncontrolled diabetes mellitus contraindication use corticosteroid Autoimmune disease ( lupus , scleroderma , rheumatoid polyarthritis ) Active grade &gt; 2 polyneuropathy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic prostate cancer</keyword>
</DOC>